EXEL
NASDAQ · Biotechnology
Exelixis Inc
$72.09
+2.52 (+3.62%)
Financial Highlights (FY 2026)
Revenue
1.97B
Net Income
665.40M
Gross Margin
96.4%
Profit Margin
33.7%
Rev Growth
+12.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 96.4% | 96.4% | 35.4% | 35.4% |
| Operating Margin | 37.6% | 33.8% | -2.4% | -2.5% |
| Profit Margin | 33.7% | 32.0% | -2.9% | -3.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.97B | 1.75B | 2.68B | 3.17B |
| Gross Profit | 1.90B | 1.68B | 949.99M | 1.12B |
| Operating Income | 741.56M | 590.99M | -63,688,410 | -79,261,053 |
| Net Income | 665.40M | 530.29M | -77,688,294 | -100,603,820 |
| Gross Margin | 96.4% | 96.4% | 35.4% | 35.4% |
| Operating Margin | 37.6% | 33.8% | -2.4% | -2.5% |
| Profit Margin | 33.7% | 32.0% | -2.9% | -3.2% |
| Rev Growth | +12.9% | +12.9% | +9.9% | +16.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 749.88M | 797.27M |
| Total Equity | — | — | 4.56B | 4.48B |
| D/E Ratio | — | — | 0.16 | 0.18 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 766.32M | 644.65M | -84,355,918 | -102,546,027 |
| Free Cash Flow | — | — | -70,301,392 | -100,328,120 |